Cerebrovascular disease risk factors: Neuroradiologic findings in patients with activated protein C resistance

Radiology

Volumn 207, Issue 1, 1998, Pages 85-90

  Provenzale, James M ^a   Barboriak, Daniel P ^a   Davey, Ian C ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Blood, coagulation; Brain, CT; Brain, infarction; Brain, MR; Carotid arteries, thrombosis; Cerebral blood vessels, thrombosis; Proteins; Sinuses, dural

Indexed keywords

ACTIVATED PROTEIN C;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN ANGIOGRAPHY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; STROKE; THROMBOSIS;

EID: 0031961470     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.207.1.9530303     Document Type: Article

References (26)

1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-1008.
2. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85:607-614.
3. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995; 15:783-785.
4. Press RD, Liu YY, Beamer N, Coull BM. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke 1996; 27:44-48.
5. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94:2521-2524.
6. Dulli DA, Luzzio CC, Williams EC, Schutta HS. Cerebral venous thrombosis and activated protein C resistance. Stroke 1996; 27:1731-1733.
7. Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996; 27:1724-1730.
8. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996; 27:1721-1723.
9. Vuillier F, Moulin T, Tatu L, Rumbach L, Bertrand MA. Isolated cortical vein thrombosis and activated protein C resistance. Stroke 1996; 27:1440-1441.
10. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannuci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1995; 75:393-394.
11. Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A. Ischemic stroke in young patients with activated protein C resistance: a report of three cases belonging to three different kindreds. Stroke 1995; 26:885-890.
12. Halbmayer WM, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5:51-57.
13. Macko RF, Gruber A, Griffin JH, et al. Low circulating activated protein C levels in ischemic stroke (abstr). Thromb Haemost 1993; 69:626.
14. Fisher M, Fernandez JA, Ameriso SF, et al. Activated protein C resistance in ischemic stroke not due to factor V arginine506 - >glutamine mutation. Stroke 1996; 27: 1163-1166.
15. Provenzale JM, Barboriak DP, Ortel TL. Durai sinus thrombosis associated with activated protein C resistance: imaging findings and proband identification. AJR 1998; 170:499-502.
16. Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97:233-238.
17. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82:1989-1993.
18. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke J, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506.
19. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-522.
20. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
21. Greengard JS, Sun X, Xu X, Fernandez JA, Evatt B, Griffin JH. Activated protein C resistance caused by Arg506Gln mutation in factor Va (letter). Lancet 1994; 343: 1361-1362.
22. Simioni P, et al. Unpublished data. Cited by: Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A. Ischemic stroke in young patients with activated protein C resistance: a report of three cases belonging to three different kindreds. Stroke 1995; 26:885-890.
23. Bogousslavsky J, Pierre P. Ischemic stroke in patients under age 45. Neurol Clin 1992; 10:113-124.
24. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993; 70:1067-1071.
25. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90:725-727.
26. Brey R, Coull BM. Cerebral venous thrombosis: role of activated protein C resistance and factor V gene mutation. Stroke 1996; 27:1719-1720.